Compare CETX & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | GOVX |
|---|---|---|
| Founded | 1998 | 2001 |
| Country | United States | United States |
| Employees | 244 | 17 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | N/A | N/A |
| Metric | CETX | GOVX |
|---|---|---|
| Price | $3.85 | $1.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 321.7K | ★ 3.1M |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.12 |
| 52 Week High | $9.70 | $4.40 |
| Indicator | CETX | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 43.35 |
| Support Level | $0.68 | $1.15 |
| Resistance Level | $6.24 | $2.00 |
| Average True Range (ATR) | 0.47 | 0.23 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 47.62 | 17.19 |
Cemtrex Inc is a multi-industry technology company. It has expanded into a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security systems. The company's operating segment includes the Security segment and the Industrial Services segment. The security segment provides end-to-end security to all industrial, corporate, and governmental security via its owned subsidiary, Vicon. Whereas the AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in-plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment, and from the USA. It also operates UK, USA, and Other.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.